- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05169567
Abemaciclib (LY2835219) más fulvestrant en comparación con placebo más fulvestrant en cáncer de mama tratado previamente (postMONARCH)
postMONARCH: un estudio de fase 3 aleatorizado, doble ciego, controlado con placebo para comparar la eficacia de abemaciclib más fulvestrant con placebo más fulvestrant en participantes con cáncer de mama HR+, HER2-, avanzado o metastásico después de la progresión con un inhibidor de CDK4 y 6 y endocrino Terapia
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Acceso ampliado
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
San Juan, Argentina, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, Argentina, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, Argentina, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., Argentina, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Centro Medico San Roque
-
-
-
-
-
Namur, Bélgica, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, Bélgica, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, Bélgica, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Hradec Králové, Chequia, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, Chequia, 53203
- Multiscan
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Corea del Sur, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Corea del Sur, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], Corea del Sur, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, Corea del Sur, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Dinamarca, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, Dinamarca, 7400
- Regionshospitalet Gødstrup
-
-
-
-
-
Badajoz, España, 06006
- Hospital Infanta Cristina
-
Madrid, España, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, España, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], España, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], España, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], España, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], España, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, España, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, España, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, España, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], España, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, España, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, Estados Unidos, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, Estados Unidos, 92835
- Providence Medical Foundation
-
Los Alamitos, California, Estados Unidos, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Estados Unidos, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, Estados Unidos, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, Estados Unidos, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, Estados Unidos, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, Estados Unidos, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, Estados Unidos, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, Estados Unidos, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, Estados Unidos, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, Estados Unidos, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, Estados Unidos, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, Estados Unidos, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, Estados Unidos, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, Estados Unidos, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, Estados Unidos, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, Estados Unidos, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, Estados Unidos, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, Estados Unidos, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, Estados Unidos, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, Estados Unidos, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, Estados Unidos, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, Estados Unidos, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, Estados Unidos, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, Estados Unidos, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, Estados Unidos, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, Estados Unidos, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Estados Unidos, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Estados Unidos, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, Estados Unidos, 76022
- Texas Oncology - Bedford
-
Denton, Texas, Estados Unidos, 76201
- Texas Oncology - Denton
-
El Paso, Texas, Estados Unidos, 79902
- Texas Oncology, P.A.
-
Houston, Texas, Estados Unidos, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, Estados Unidos, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, Estados Unidos, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, Estados Unidos, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, Estados Unidos, 75093
- Texas Oncology-Plano West
-
Plano, Texas, Estados Unidos, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, Estados Unidos, 78229
- Mays Cancer Center
-
The Woodlands, Texas, Estados Unidos, 77380
- US Oncology
-
Tyler, Texas, Estados Unidos, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, Estados Unidos, 84107
- Intermountain Medical Center
-
St. George, Utah, Estados Unidos, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, Estados Unidos, 22601
- Shenandoah Oncology, P.C.
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, Francia, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, Francia, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Francia, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, Francia, 85000
- CHD Vendee
-
-
-
-
-
Thessaloniki, Grecia, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, Grecia, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, Grecia, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, Grecia, 711 10
- University General Hospital of Heraklion
-
-
-
-
-
Budapest, Hungría, 1122
- Országos Onkológiai Intézet
-
Budapest, Hungría, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Hungría, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Hungría, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
-
-
Central District
-
Kfar Saba, Central District, Israel, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, Israel
- Rabin Medical Center
-
Ramat Gan, Central District, Israel, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, Israel, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israel, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italia, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, Italia, 58100
- Ospedale Misericordia di Grosseto
-
Milan, Italia, 20132
- Ospedale San Raffaele
-
Viterbo, Italia, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, Italia, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italia, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italia, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, México, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, México, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, México, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, México, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, México, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, Polonia, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polonia, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
Stockholms
-
Stockholm, Stockholms, Suecia, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], Suecia, 701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Kaohsiung City, Taiwán, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwán, 231
- Taipei Tzu Chi General Hospital
-
Taipei, Taiwán, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwán, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taiwán, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, Taiwán, 71004
- Chi Mei Medical Center
-
-
-
-
-
Adana, Turquía (Türkiye), 01370
- Adana City Hospital
-
Ankara, Turquía (Türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, Turquía (Türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, Turquía (Türkiye), 21200
- Dicle Üniversitesi
-
Edirne, Turquía (Türkiye), 22030
- Trakya University
-
Istanbul, Turquía (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, Turquía (Türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, Turquía (Türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, Turquía (Türkiye), 009035575
- Izmir Medical Park Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
Comparador activo: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Periodo de tiempo: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Periodo de tiempo: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publicaciones y enlaces útiles
Publicaciones Generales
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Procesos Neoplásicos
- Enfermedades de la piel
- Enfermedades de los senos
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades de la piel y del tejido conectivo
- Neoplasias de mama
- Metástasis de neoplasias
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Compuestos policíclicos
- Esteroides
- Compuestos de anillo fusionado
- Estradiol
- Estreness
- Estranos
- Congéneres de estradiol
- Hormonas esteroides gonadal
- Hormonas gonadales
- Fulvestrant
- abemaciclib
Otros números de identificación del estudio
- 18238
- I3Y-MC-JPEF (Otro identificador: Eli Lilly and Company)
- 2021-002301-10 (Número EudraCT)
- 2023-506771-10-00 (Otro identificador: EU Trial Number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Marco de tiempo para compartir IPD
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Criterios de acceso compartido de IPD
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .